Hookipa Pharma (NASDAQ:HOOK) Shares Up 5.9%

Shares of Hookipa Pharma Inc (NASDAQ:HOOK) shot up 5.9% during mid-day trading on Wednesday . The company traded as high as $11.76 and last traded at $11.11. 421,600 shares traded hands during mid-day trading, an increase of 482% from the average session volume of 72,444 shares. The stock had previously closed at $10.49.

A number of brokerages recently issued reports on HOOK. Royal Bank of Canada reissued a “buy” rating and issued a $18.00 price objective on shares of Hookipa Pharma in a report on Sunday, August 16th. Zacks Investment Research lowered Hookipa Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, August 18th. ValuEngine raised Hookipa Pharma from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Hookipa Pharma in a research note on Wednesday, June 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. Hookipa Pharma has a consensus rating of “Hold” and a consensus price target of $15.00.

The firm has a market capitalization of $242.59 million, a P/E ratio of -7.12 and a beta of 1.15. The company has a debt-to-equity ratio of 0.08, a quick ratio of 6.35 and a current ratio of 6.35. The firm has a 50 day moving average price of $9.80 and a two-hundred day moving average price of $9.80.

Hookipa Pharma (NASDAQ:HOOK) last released its earnings results on Thursday, August 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.18. Hookipa Pharma had a negative return on equity of 34.74% and a negative net margin of 247.22%. The company had revenue of $6.69 million during the quarter, compared to analyst estimates of $2.81 million. Equities research analysts forecast that Hookipa Pharma Inc will post -1.61 earnings per share for the current fiscal year.

In related news, major shareholder Sofinnova Capital Vi Fcpr sold 12,483 shares of the business’s stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $11.94, for a total value of $149,047.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.02% of the company’s stock.

A number of hedge funds have recently bought and sold shares of HOOK. BNP Paribas Arbitrage SA grew its holdings in shares of Hookipa Pharma by 114.3% during the first quarter. BNP Paribas Arbitrage SA now owns 3,262 shares of the company’s stock valued at $27,000 after buying an additional 1,740 shares during the last quarter. Citigroup Inc. grew its stake in shares of Hookipa Pharma by 118.1% during the first quarter. Citigroup Inc. now owns 4,360 shares of the company’s stock worth $36,000 after acquiring an additional 2,361 shares during the last quarter. Wells Fargo & Company MN boosted its position in Hookipa Pharma by 626.7% in the first quarter. Wells Fargo & Company MN now owns 6,795 shares of the company’s stock valued at $56,000 after buying an additional 5,860 shares during the last quarter. Royal Bank of Canada boosted its position in Hookipa Pharma by 81.6% in the first quarter. Royal Bank of Canada now owns 8,253 shares of the company’s stock valued at $68,000 after buying an additional 3,709 shares during the last quarter. Finally, American International Group Inc. boosted its position in Hookipa Pharma by 28.8% in the second quarter. American International Group Inc. now owns 7,602 shares of the company’s stock valued at $88,000 after buying an additional 1,702 shares during the last quarter. Hedge funds and other institutional investors own 34.01% of the company’s stock.

Hookipa Pharma Company Profile (NASDAQ:HOOK)

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.

See Also: What is a put option?

Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.